Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma

References

• Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, et al. 2013. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 58(4):1253–1262. doi: 10.1002/hep.26442
   PubMed Web of Science ®Google Scholar
• Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, et al. 2020. Real-world clinical application of 12-Week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Infect Dis Ther. 9(4):851–866. doi: 10.1007/s40121-020-00329-y
   PubMed Web of Science ®Google Scholar
• Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, et al. 2019. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 49(9):1230–1241. doi: 10.1111/apt.15218
   PubMed Web of Science ®Google Scholar
• Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, et al. 2016. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 14(6):875–886 e876. doi: 10.1016/j.cgh.2015.12.042
   PubMed Web of Science ®Google Scholar
• Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. 2012. Hepatocellualar carcinoma serum markers. Semin Oncol. 39(4):410–433. doi: 10.1053/j.seminoncol.2012.05.001
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Brierley DJ, Gospodarowicz KM, Wittekind C. 2017. TNM classification of malignant tumours. 8th ed. Oxford (UK): Wiley-Blackwell in affiliation with the Union for International Cancer Control (UICC); p. 90–93.
   Google Scholar
• Bruix J, Sherman M. . 2011. Management of hepatocellular carcinoma: an update. Hepatology. 53(3):1020–1022. doi: 10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Cao M, Gao J, Zhou H, Huang J, You A, Guo Z, Fang F, Zhang W, Song T, Zhang T. 2016. HIF-2alpha regulates CDCP1 to promote PKCdelta-mediated migration in hepatocellular carcinoma. Tumour Biol. 37(2):1651–1662. doi: 10.1007/s13277-015-3527-7
   PubMedGoogle Scholar
• Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. 2019. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 69(5):1983–1994. doi: 10.1002/hep.30233
   PubMed Web of Science ®Google Scholar
• Diehl AM, Day C. 2017. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 377(21):2063–2072. doi: 10.1056/NEJMra1503519
   PubMed Web of Science ®Google Scholar
• EASL. 2018. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 69(1):182–236. doi: 10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, et al. 2018. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 69(4):896–904. doi: 10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Tashiro H, Kobayashi T, Kuroda S, Hamaoka M, Ohdan H. 2017. Clinical characteristics and prognosis of non-B, non-C hepatocellular carcinoma: the impact of patient sex on disease-free survival - A retrospective cohort study. Int J Surg. 39:206–213. doi: 10.1016/j.ijsu.2017.01.110
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Sherbondy M. 2006. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 74(5):767– 776.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. 2018. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 67(1):358–380. doi: 10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. 2012. Gene signatures in the management of hepatocellular carcinoma. Semin Oncol. 39(4):473–485. doi: 10.1053/j.seminoncol.2012.05.003
   PubMed Web of Science ®Google Scholar
• Hsu PY, Hsu CT, Yeh ML, Huang CF, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Hsieh MH, Dai CY, et al. 2020. Early fibrosis but late tumor stage and worse outcomes in hepatocellular carcinoma patients without hepatitis B or hepatitis C. Dig Dis Sci. 65(7):2120–2129. doi: 10.1007/s10620-019-05938-3
   PubMed Web of Science ®Google Scholar
• Hsu PY, Liang PC, Huang CI, Hsieh MH, Tsai YS, Lin TC, Yeh ML, Huang CF, Wang CW, Jang TY, et al. 2022. Effects of achieving SVR on clinical characteristics and surgical outcomes in patients who developed early-stage hcv-related hepatocellular carcinoma and received curative resection: preoperative versus postoperative SVR. Viruses. 14(11):2412. doi: 10.3390/v14112412
   PubMed Web of Science ®Google Scholar
• Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, et al. 1999. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 29(4):1124–1130. doi: 10.1002/hep.510290439
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Green PK, Berry K. 2017. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 5:S0168-8278(17)32273–0. doi: 10.1016/j.jhep.2017.08.030
   Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, et al. 2014. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 23(1):144–153. doi: 10.1158/1055-9965.EPI-13-0870
   PubMed Web of Science ®Google Scholar
• Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, et al. 2019. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 49(10):1109–1113. doi: 10.1111/hepr.13411
   PubMed Web of Science ®Google Scholar
• Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. 1984. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 310(22):1427–1431. doi: 10.1056/NEJM198405313102204
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, et al. 2009. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 137(1):110–118. doi: 10.1053/j.gastro.2009.04.005
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. 2018. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 68(2):723–750. doi: 10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, et al. 2015. Serum alpha-fetoprotein has high specificity for the early detection of hepatocellular carcinoma after hepatitis C virus eradication in patients. Medicine. 94(23):e901. doi: 10.1097/MD.0000000000000901
   PubMed Web of Science ®Google Scholar
• Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, , et al. 2020. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 14(2):225–238. doi: 10.1007/s12072-020-10019-z
   PubMed Web of Science ®Google Scholar
• Oikawa T. 2016. Cancer stem cells and their cellular origins in primary liver and biliary tract cancers. Hepatology. 64(2):645–651. doi: 10.1002/hep.28485
   PubMed Web of Science ®Google Scholar
• Oikawa T, Yamada K, Tsubota A, Saeki C, Nakagawa C, Ueda K, Kamioka H, Taniai T, Haruki K, Nakano M, et al. 2023. Protein kinase C delta is a novel biomarker for hepatocellular carcinoma. GasroHep Advances. 2(1):83–95. doi: 10.1016/j.gastha.2022.07.020
   Google Scholar
• Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al. 2017. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 11(4):317–370. doi: 10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, et al. 2012. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol. 47(4):444–451. doi: 10.1007/s00535-011-0505-8
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, et al. 2015. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35(9):2155–2166. doi: 10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Lalrean, et al. 2019. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int. 39(6):1033–1043., doi: 10.1111/liv.14041
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al. 2022. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 76(3):681–693. doi: 10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, , et al. 2023. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 79(6):1542–1556. doi: 10.1016/j.jhep.2023.06.003
   PubMed Web of Science ®Google Scholar
• Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh ND, Browning T, Singal AG. 2017. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 45(1):169–177. doi: 10.1111/apt.13841
   PubMed Web of Science ®Google Scholar
• Singal AG, Lampertico P, Nahon P. 2020. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 72(2):250–261. doi: 10.1016/j.jhep.2019.08.025
   PubMed Web of Science ®Google Scholar
• Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. 2010. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 51(2):595–602. doi: 10.1002/hep.23314
   PubMed Web of Science ®Google Scholar
• Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. 2012. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 107(1):64–74. doi: 10.1038/ajg.2011.312
   PubMed Web of Science ®Google Scholar
• Taketa K. 1990. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 12(6):1420–1432. doi: 10.1002/hep.1840120625
   PubMed Web of Science ®Google Scholar
• Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, et al. 2019. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol. 54(4):367–376. doi: 10.1007/s00535-018-1532-5
   PubMed Web of Science ®Google Scholar
• Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, et al. 2022a. The impact of cirrhosis and history of hepatocellular carcinoma on all-cause mortality after eradication of hepatitis C virus in patients with chronic hepatitis C. Gastro Hep Advances. 1(4):508–515. doi: 10.1016/j.gastha.2022.0
   Google Scholar
• Toyoda H, Kariyama K, Hiraoka A, Tsuji K, Ishikawa T, Hatanaka T, Naganuma A, Yasuda S, Nouso K, Kakizaki S, et al. 2022b. Improved survival of viral hepatocellular carcinoma but not non-viral hepatocellular carcinoma from 2000 to 2020: a multi-centre cohort study of 6007 patients from high volume academic centres in Japan. Aliment Pharmacol Ther. 56(4):694–701. doi: 10.1111/apt.17088
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. 2015. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 4(2):126–136. doi: 10.1159/000367735
   PubMed Web of Science ®Google Scholar
• Tsai JH, Hsieh YS, Kuo SJ, Chen ST, Yu SY, Huang CY, Chang AC, Wang YW, Tsai MT, Liu JY. 2000. Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma. Cancer Lett. 161(2):171–175. doi: 10.1016/s0304-3835(00)00597-8
   PubMed Web of Science ®Google Scholar
• Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, et al. 2015. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 261(3):513–520. doi: 10.1097/SLA.0000000000000821
   PubMed Web of Science ®Google Scholar
• Wakiyama S, Matsumoto M, Haruki K, Gocho T, Sakamoto T, Shiba H, Futagawa Y, Ishida Y, Yanaga K. 2017. Clinical features and outcome of surgical patients with non-B non-C hepatocellular carcinoma. Anticancer Res. 37(6):3207–3213. doi: 10.21873/anticanres.11682
   PubMed Web of Science ®Google Scholar
• Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. 2011. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 54(2):463–471. doi: 10.1002/hep.24397
   PubMed Web of Science ®Google Scholar
• Wu TT, Hsieh YH, Wu CC, Hsieh YS, Huang CY, Liu JY. 2007. Overexpression of protein kinase C alpha mRNA in human hepatocellular carcinoma: a potential marker of disease prognosis. Clin Chim Acta. 382(1-2):54–58. doi: 10.1016/j.cca.2007.03.018
   PubMed Web of Science ®Google Scholar
• Yamada K, Kizawa R, Yoshida A, Koizumi R, Motohashi S, Shimoyama Y, Hannya Y, Yoshida S, Oikawa T, Shimoda M, et al. 2022a. Extracellular PKCdelta signals to epidermal growth factor receptor for tumor proliferation in liver cancer cells. Cancer Sci. 113(7):2378–2385. doi: 10.1111/cas.15386
   PubMed Web of Science ®Google Scholar
• Yamada K, Motohashi S, Oikawa T, Tago N, Koizumi R, Ono M, Tachibana T, Yoshida A, Yoshida S, Shimoda M, et al. 2022b. Extended-synaptotagmin 1 engages in unconventional protein secretion mediated via SEC22B(+) vesicle pathway in liver cancer. Proc Natl Acad Sci U S A. 119(36):e2202730119. doi: 10.1073/pnas.2202730119
   PubMed Web of Science ®Google Scholar
• Yamada K, Oikawa T, Kizawa R, Motohashi S, Yoshida S, Kumamoto T, Saeki C, Nakagawa C, Shimoyama Y, Aoki K, et al. 2021. Unconventional secretion of PKCdelta exerts tumorigenic function via stimulation of ERK1/2 signaling in liver cancer. Cancer Res. 81(2):414–425. doi: 10.1158/0008-5472.CAN-20-2009
   PubMed Web of Science ®Google Scholar
• Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, et al. 2021. Characteristics and survival outcomes of hepatocellular carcinoma developed after HCV SVR. Cancers. 13(14):3455. doi: 10.3390/cancers13143455
   PubMed Web of Science ®Google Scholar
• Yoon CH, Kim MJ, Park MJ, Park IC, Hwang SG, An S, Choi YH, Yoon G, Lee SJ. 2010. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem. 285(1):226–233. doi: 10.1074/jbc.M109.054189
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. 2016. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64(1):73–84. doi: 10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. 2015. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 62(6):1723–1730. doi: 10.1002/hep.28123
   PubMed Web of Science ®Google Scholar